Komal Jhaveri

Dr. Komal Jhaveri, a breast medical oncologist at Memorial Sloan Kettering, shares her expertise on the significance of HER2 testing in metastatic hormone receptor positive breast cancer. She discusses groundbreaking findings from the DESTINY Breast-04 and -06 studies, exploring low and ultra-low HER2 expressions, and the implications for treatment options. Dr. Jhaveri highlights the importance of antibody-drug conjugates like T-DXd, while addressing management strategies for treatment-related toxicities, making this a must-listen for healthcare professionals.